Stomach Cancer Treatment Market to Register 15.3% CAGR till 2026; Growing Number of Gastric Adenocarcinoma Cases to Favor Market Expansion

The global stomach cancer/gastric cancer treatment market size is projected to touch USD 8.20 billion by 2026 as health reimbursement policies for cancer patients get more favorable in developing countries. According to the new Fortune Business Insights report, titled “Stomach Cancer/Gastric Cancer Treatment Market Size, Share & Industry Analysis, By Drug Type (Programmed Cell Death Protein 1 (PD-1) Inhibitors, Human Epidermal Growth Factor Receptor (HER2) Antagonists, Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists, and Others), By Disease Indication (Gastric Adenocarcinoma, Gastrointestinal Stromal Tumor (GIST), and Gastric Neuroendocrine Tumors (gNET)), By Route of Administration (Oral and Parenteral) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Regional Forecast, 2019-2026”, the value of this market was at USD 2.61 billion in 2018. The report additionally states that the market will surge at a CAGR of 15.3% from 2019 and 2026.

Increasing Incidence of Gastric Cancer to Broaden Sales Horizons

Chief among the gastric cancer treatment market trends is the rising prevalence of stomach cancer across the globe that is ramping up the demand for gastric carcinoma drugs. As per the statistics of the World Health Organization (WHO), in 2018, approximately 1.03 million people were suffering from stomach cancer. By 2025, the WHO predicts, this number will shoot up to reach 1.24 million. In the US alone, according to the American Society of Clinical Oncology, 27,510 people were diagnosed with stomach cancer in 2019. With growing incidence of stomach cancer, the need for effective gastric carcinoma drugs is likely to become urgent in the forthcoming years.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/stomach-gastric-cancer-treatment-market-102094

Market Segmentation:

• By Drug Type: Based on drug type, the market is classified into Programmed Cell Death Protein 1 (PD-1) inhibitors, Human Epidermal Growth Factor Receptor (HER2) antagonists, Vascular Endothelial Growth Factor Receptor (VEGFR) antagonists, and others. Among these, the PD-1 inhibitors segment is slated to lead with a mighty share of 61.1%, mainly on account of advancing research on PD-1 inhibitors and introduction of new products in the market. The other segments are also expected to grow at a steady pace during the forecast period.


• By Disease Indication: In terms of disease indication, the stomach cancer treatment market is segmented into gastric adenocarcinoma, gastrointestinal stromal tumors (GIST), and gastric Neuroendocrine Tumors (gNET). Here, the gastric adenocarcinoma segment is foreseen to dictate the market owing to the speedy uptake of immuno-checkpoint inhibitors and targeted therapies for treating this affliction. The other remaining segments are also expected to rise considerably in the near future.


• By Route of Administration: On the basis of route of administration, the market is divided into oral and parenteral. Both segments are anticipated to showcase healthy growth, according to the stomach cancer treatment market analysis. In case of the oral segment, convenience of administration will be the key factor driving this segment. In case of the parenteral segment, availability of intravenous drugs and supportive health reimbursement policies will be central for this segment’s rise. 


• By Distribution Channel: Based on distribution channel, the market is grouped into hospital pharmacy, retail pharmacy, and online pharmacy. Among these, the hospital pharmacy segment is set to lead as government-funded and aided hospitals are receiving unflinching support from government healthcare policies and budgeting, especially in emerging economies. The other segments are also anticipated to grow considerably in the forecast period.


• By Region: Geographically, the market is segregated into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Asia Pacific is poised to dominate the gastric cancer treatment market share by generating a revenue of USD 1.01 billion in 2018. The major reason for this is the ready adoption of PD-1 inhibitors in India and China as the prevalence of gastric carcinoma in these countries is steadily rising. Furthermore, this region is home to regular new product launches by companies, which is accelerating the gastric cancer treatment market revenue. The other regions are also anticipated to offer promising prospects in the foreseeable future.

Presence of a Few Big Players to Stiffen Market Competition

The gastric carcinoma drugs market competition is characterized by the dominance of a few key players, who are focusing on their pipeline candidates to consolidate their position in this market. Some of the prominent players profiled in the stomach cancer treatment market report include:

• Ipsen Pharma


• Bristol-Myers Squibb Company


• Bayer AG


• Merck & Co., Inc.


• Eli Lilly and Company


• Jiangsu Hengrui Medicine Co., Ltd.


• TAIHO PHARMACEUTICAL CO., LTD.


• Celltrion Inc.


• Novartis AG


• F. Hoffmann-La Roche Ltd

Industry Developments:

• November 2019: EMD Serono and Pfizer collaborated to conduct a joint clinical study on Avelumab, their advanced gastric cancer product, whose Phase III was successfully completed.


• March 2019: AstraZeneca signed an agreement with Daiichi Sankyo to commercially distribute the company’s antibody drug conjugate for treating gastric carcinoma, trastuzumab deruxtecan.

The Global Stomach Cancer/Gastric Cancer Treatment Market is Segmented as Follows: